Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Biogen Idec, Isis partner on antisense drug
August 2012
SHARING OPTIONS:

WESTON, Mass.—An exclusive, worldwide option and collaboration agreement has been established between Biogen Idec and Isis Pharmaceuticals Inc., under which the companies will develop and commercialize a novel antisense drug to treat myotonic dystrophy type 1, also known as Steinert disease. Biogen Idec will pay Isis $12 million upfront, and has the option to license the drug from Isis up through the end of the Phase II trial. Isis stands to receive up to $59 million in milestone payments associated with clinical development, up to an additional $200 million in a license fee and regulatory milestone payments and double-digit royalties on sales of the drug. Isis is responsible for global development through the completion of Phase II clinical trials, and if Biogen Idec exercises its option, it will assume responsibility for global development, regulatory and commercialization duties.          


Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.